Gesamter Bestand

Auflistung Nach Schlagwort "liver cirrhosis"

Anzeige der Dokumente 1-20 von 41

    • Acute non-A, non-B, non-C hepatitis differences and similarities between hepatitis E virus infection and autoimmune hepatitis, with phylogenetic analysis of hepatitis E virus in humans and wild boars 

      Zachou K., Azariadis K., Sofia M., Lyberopoulou A., Arvaniti P., Gatselis N., Spyrou V., Billinis C., Dalekos G.N. (2022)
      Background Hepatitis E virus (HEV) infection incidence is increasing in Europe, accounting for the majority of acute hepatitis cases. We investigated the prevalence and clinical characteristics of acute hepatitis E (AHE) ...

    • Aiming towards hepatitis C virus elimination in Greece 

      Papatheodoridis G.V., Goulis J., Sypsa V., Lionis C., Manolakopoulos S., Elefsiniotis I., Anagnostou O., Tsoulas C., Hatzakis A., Dalekos G.N. (2019)
      There are estimated to be 74,000-134,000 patients living with chronic hepatitis C in Greece, but only 20-30% of them are aware of their disease status. In July 2017, the Hellenic National Plan for Hepatitis C was announced ...

    • aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis 

      Fan R., Papatheodoridis G., Sun J., Innes H., Toyoda H., Xie Q., Mo S., Sypsa V., Guha I.N., Kumada T., Niu J., Dalekos G., Yasuda S., Barnes E., Lian J., Suri V., Idilman R., Barclay S.T., Dou X., Berg T., Hayes P.C., Flaherty J.F., Zhou Y., Zhang Z., Buti M., Hutchinson S.J., Guo Y., Calleja J.L., Lin L., Zhao L., Chen Y., Janssen H.L.A., Zhu C., Shi L., Tang X., Gaggar A., Wei L., Jia J., Irving W.L., Johnson P.J., Lampertico P., Hou J. (2020)
      Background & Aims: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the ...

    • Assessment of adrenal response in patients with stable cirrhosis and ascites using different short Synacthen tests and definitions 

      Kalambokis G.N., Tsiakas I., Christaki M., Despotis G., Fillipas-Ntekuan S., Xourgia X., Fotopoulos A., Bargiota A., Stilopoulou S., Tigas S., Bairaktari E., Kolios G., Koustousi C., Aggelis N., Sergianiti F., Milionis H. (2021)
      BACKGROUND AND AIMS: The definition of relative adrenal insufficiency (RAI) in patients with cirrhosis remains controversial. We investigated the serum and salivary cortisol (SalC) response after low-dose and standard-dose ...

    • Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome 

      Keskin O., Wedemeyer H., Tüzün A., Zachou K., Deda X., Dalekos G.N., Heidrich B., Pehlivan S., Zeuzem S., Yalçin K., Gürel S., Tabak F., Idilman R., Bozkaya H., Manns M., Yurdaydin C. (2015)
      Background & Aims: Interferon is the only effective treatment for chronic hepatitis D virus (HDV) infection. No rules have been set for stopping treatment based on viral kinetics. We analyzed data from an international ...

    • Association of antiviral therapy with reduced disease progression in chronic hepatitis b patients: Results from a nation-wide cohort study 

      Vourli G., Papatheodoridis G., Raptopoulou M., Dalekos G.N., Hounta A., Nikolopoulou G., Zouboulis-Vafeiadis I., Manesis E., Kitis G., Gogos C., Ketikoglou I., Hatzis G., Vasilialdis T., Karatapanis S., Mimidis K., Drakoulis C., Touloumi G., The Hepnet-Greece Study (2016)
      Background and Aims: Although effective treatment in terms of inducing virological and biochemical response for chronic hepatitis B (CHB) is available, its effect on the clinical course of the disease has not yet been ...

    • Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis 

      Arvaniti P., Giannoulis G., Gabeta S., Zachou K., Koukoulis G.K., Dalekos G.N. (2020)
      Background & Aims: Autoimmune hepatitis (AIH) is a disease of unknown aetiology with a favourable response to immunosuppression. However, in the clinic, it appears that <50% of patients achieve complete response on standard ...

    • Caffeine metabolism in liver cirrhosis 

      Begas, E.; Asprodini, E. K.; Papakosta, S.; Maglaras, L.; Benakis, A.; Dalekos, G. (2005)
      Caffeine is metabolized primarily by CYP1A2. Several methods have been developed for the in vivo assessment of CYP1A2 activity using caffeine as a probe drug (2). These methods include the determination of caffeine clearance ...

    • Cartilage oligomeric matrix protein on the spot for liver fibrosis evaluation: Too early or too late? 

      Zachou K., Gabeta S., Gatselis N.K., Norman G.L., Dalekos G.N. (2017)
      [No abstract available]

    • Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN) 

      Wranke A., Pinheiro Borzacov L.M., Parana R., Lobato C., Hamid S., Ceausu E., Dalekos G.N., Rizzetto M., Turcanu A., Niro G.A., Lubna F., Abbas M., Ingiliz P., Buti M., Ferenci P., Vanwolleghem T., Hayden T., Dashdorj N., Motoc A., Cornberg M., Abbas Z., Yurdaydin C., Manns M.P., Wedemeyer H., Hardtke S., Serrano B., Wöbse M., Heidrich B., Muche M., Gatselis N., Zachou K., Ho E., Smedile A., Fontana R., Gish R., Obretin D., Stern R., the Hepatitis Delta International Network (2018)
      Background & Aims: Chronic hepatitis D (delta) is a major global health burden. Clinical and virological characteristics of patients with hepatitis D virus (HDV) infection and treatment approaches in different regions ...

    • COMP serum levels: A new non-invasive biomarker of liver fibrosis in patients with chronic viral hepatitis 

      Zachou K., Gabeta S., Shums Z., Gatselis N.K., Koukoulis G.K., Norman G.L., Dalekos G.N. (2017)
      Background & aims Recently we have shown that cartilage oligomeric matrix protein (COMP), a fibrillar collagen assembly regulator, is strongly associated with cirrhosis and hepatocellular carcinoma progression. Therefore, ...

    • Cryoglobulinemia due to chronic viral hepatitis infections is not a major problem in clinical practice 

      Christodoulou, D. K.; Dalekos, G. N.; Merkouropoulos, M. H.; Kistis, K. G.; Georgitsi, G.; Zervou, E.; Zachou, K.; Tsianos, E. V. (2001)
      Background: Essential mixed cryoglobulinemia (EMC) is a systemic disease frequently associated with chronic viral hepatitis. This study was conducted in order to assess the prevalence of EMC in patients with hepatitis B ...

    • Daring-B: Discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B 

      Papatheodoridis G.V., Rigopoulou E.I., Papatheodoridi M., Zachou K., Xourafas V., Gatselis N., Hadziyannis E., Vlachogiannakos J., Manolakopoulos S., Dalekos G.N. (2018)
      Background: The remission rates after stopping antivirals in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) vary among studies, while reliable predictors of relapse have not been identified. This prospective ...

    • Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population 

      Papatheodoridis G.V., Sypsa V., Dalekos G., Yurdaydin C., van Boemmel F., Buti M., Goulis J., Calleja J.L., Chi H., Manolakopoulos S., Loglio A., Siakavellas S., Gatselis N., Keskın O., Lehretz M., Savvidou S., de la Revilla J., Hansen B.E., Kourikou A., Vlachogiannakos I., Galanis K., Idilman R., Colombo M., Esteban R., Janssen H.L.A., Berg T., Lampertico P. (2018)
      Background & Aims: The effects of long-term antiviral therapy on survival have not been adequately assessed in chronic hepatitis B (CHB). In this 10-centre, ongoing cohort study, we evaluated the probability of survival ...

    • FibroMeter scores for the assessment of liver fibrosis in patients with autoimmune liver diseases 

      Zachou K., Lygoura V., Arvaniti P., Giannoulis G., Gatselis N.K., Koukoulis G.K., Dalekos G.N. (2021)
      Introduction and Objectives: We assessed FibroMeter virus (FMvirus) and FibroMeter vibration-controlled transient elastography (FMVCTE) in 134 patients with autoimmune liver diseases [ALD, autoimmune hepatitis (AIH) and ...

    • Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016 

      Naghavi M., Abajobir A.A., Abbafati C., Abbas K.M., Abd-Allah F., Abera S.F., Aboyans V., Adetokunboh O., Ärnlöv J., Afshin A., Agrawal A., Kiadaliri A.A., Ahmadi A., Ahmed M.B., Aichour A.N., Aichour I., Aichour M.T.E., Aiyar S., Al-Eyadhy A., Alahdab F., Al-Aly Z., Alam K., Alam N., Alam T., Alene K.A., Ali S.D., Alizadeh-Navaei R., Alkaabi J.M., Alkerwi A., Alla F., Allebeck P., Allen C., Al-Raddadi R., Alsharif U., Altirkawi K.A., Alvis-Guzman N., Amare A.T., Amini E., Ammar W., Amoako Y.A., Anber N., Andersen H.H., Andrei C.L., Androudi S., Ansari H., Antonio C.A.T., Anwari P., Arora M., Artaman A., Aryal K.K., Asayesh H., Asgedom S.W., Atey T.M., Avila-Burgos L., Avokpaho E.F.G.A., Awasthi A., Quintanilla B.P.A., Béjot Y., Babalola T.K., Bacha U., Balakrishnan K., Barac A., Barboza M.A., Barker-Collo S.L., Barquera S., Barregard L., Barrero L.H., Baune B.T., Bedi N., Beghi E., Bekele B.B., Bell M.L., Bennett J.R., Bensenor I.M., Berhane A., Bernabé E., Betsu B.D., Beuran M., Bhatt S., Biadgilign S., Bienhof K., Bikbov B., Bisanzio D., Bourne R.R.A., Breitborde N.J.K., Bulto L.N.B., Bumgarner B.R., Butt Z.A., Cárdenas R., Cahuana-Hurtado L., Cameron E., Campuzano J.C., Car J., Carrero J.J., Carter A., Casey D.C., Castañeda-Orjuela C.A., Catalá-López F., Charlson F.J., Chibueze C.E., Chimed-Ochir O., Chisumpa V.H., Chitheer A.A., Christopher D.J., Ciobanu L.G., Cirillo M., Cohen A.J., Colombara D., Cooper C., Cowie B.C., Criqui M.H., Dandona L., Dandona R., Dargan P.I., Das Neves J., Davitoiu D.V., Davletov K., De Courten B., Degenhardt L., Deiparine S., Deribe K., Deribew A., Dey S., Dicker D., Ding E.L., Djalalinia S., Do H.P., Doku D.T., Douwes-Schultz D., Driscoll T.R., Dubey M., Duncan B.B., Echko M., El-Khatib Z.Z., Ellingsen C.L., Enayati A., Erskine H.E., Eskandarieh S., Esteghamati A., Ermakov S.P., Estep K., Sa Farinha C.S., Faro A., Farzadfar F., Feigin V.L., Fereshtehnejad S.-M., Fernandes J.C., Ferrari A.J., Feyissa T.R., Filip I., Finegold S., Fischer F., Fitzmaurice C., Flaxman A.D., Foigt N., Frank T., Fraser M., Fullman N., Fürst T., Furtado J.M., Gakidou E., Garcia-Basteiro A.L., Gebre T., Gebregergs G.B., Gebrehiwot T.T., Gebremichael D.Y., Geleijnse J.M., Genova-Maleras R., Gesesew H.A., Gething P.W., Gillum R.F., Ginawi I.A.M., Giref A.Z., Giroud M., Giussani G., Godwin W.W., Gold A.L., Goldberg E.M., Gona P.N., Gopalani S.V., Gouda H.N., Goulart A.C., Griswold M., Gupta P.C., Gupta R., Gupta T., Gupta V., Haagsma J.A., Hafezi-Nejad N., Hailu A.D., Hailu G.B., Hamadeh R.R., Hambisa M.T., Hamidi S., Hammami M., Hancock J., Handal A.J., Hankey G.J., Hao Y., Harb H.L., Hareri H.A., Hassanvand M.S., Havmoeller R., Hay S.I., He F., Hedayati M.T., Henry N.J., Heredia-Pi I.B., Herteliu C., Hoek H.W., Horino M., Horita N., Hosgood H.D., Hostiuc S., Hotez P.J., Hoy D.G., Huynh C., Iburg K.M., Ikeda C., Ileanu B.V., Irenso A.A., Irvine C.M.S., Jürisson M., Jacobsen K.H., Jahanmehr N., Jakovljevic M.B., Javanbakht M., Jayaraman S.P., Jeemon P., Jha V., John D., Johnson C.O., Johnson S.C., Jonas J.B., Kabir Z., Kadel R., Kahsay A., Kamal R., Karch A., Karimi S.M., Karimkhani C., Kasaeian A., Kassaw N.A., Kassebaum N.J., Katikireddi S.V., Kawakami N., Keiyoro P.N., Kemmer L., Kesavachandran C.N., Khader Y.S., Khan E.A., Khang Y.-H., Khoja A.T.A., Khosravi A., Khosravi M.H., Khubchandani J., Kieling C., Kievlan D., Kim D., Kim Y.J., Kimokoti R.W., Kinfu Y., Kissoon N., Kivimaki M., Knudsen A.K., Kopec J.A., Kosen S., Koul P.A., Koyanagi A., Defo B.K., Kulikof X.R., Kumar G.A., Kumar P., Kutz M., Kyu H.H., Lal D.K., Lalloo R., Lambert T.L.N., Lan Q., Lansingh V.C., Larsson A., Lee P.H., Leigh J., Leung J., Levi M., Li Y., Kappe D.L., Liang X., Liben M.L., Lim S.S., Liu A., Liu P.Y., Liu Y., Lodha R., Logroscino G., Lorkowski S., Lotufo P.A., Lozano R., Lucas T.C.D., Ma S., Macarayan E.R.K., Maddison E.R., Abd El Razek M.M., Majdan M., Majdzadeh R., Majeed A., Malekzadeh R., Malhotra R., Malta D.C., Manguerra H., Manyazewal T., Mapoma C.C., Marczak L.B., Markos D., Martinez-Raga J., Martins-Melo F.R., Martopullo I., McAlinden C., McGaughey M., McGrath J.J., Mehata S., Meier T., Meles K.G., Memiah P., Memish Z.A., Mengesha M.M., Mengistu D.T., Menota B.G., Mensah G.A., Meretoja A., Meretoja T.J., Millear A., Miller T.R., Minnig S., Mirarefn M., Mirrakhimov E.M., Misganaw A., Mishra S.R., Mohammad K.A., Mohammadi A., Mohammed S., Mokdad A.H., Mola G.L.D., Mollenkopf S.K., Molokhia M., Monasta L., Hernandez J.C.M., Montico M., Mooney M.D., Moradi-Lakeh M., Moraga P., Morawska L., Morrison S.D., Morozof C., Mountjoy-Venning C., Mruts K.B., Muller K., Murthy G.V.S., Musa K.I., Nachega J.B., Naheed A., Naldi L., Nangia V., Nascimento B.R., Nasher J.T., Natarajan G., Negoi I., Ngunjiri J.W., Nguyen C.T., Nguyen G., Nguyen M., Nguyen Q.L., Nguyen T.H., Nichols E., Ningrum D.N.A., Nong V.M., Noubiap J.J.N., Ogbo F.A., Oh I.-H., Okoro A., Olagunju A.T., Olsen H.E., Olusanya B.O., Olusanya J.O., Ong K., Opio J.N., Oren E., Ortiz A., Osman M., Ota E., Mahesh P.A., Pacella R.E., Pakhale S., Pana A., Panda B.K., Jonas S., Papachristou C., Park E.-K., Patten S.B., Patton G.C., Paudel D., Paulson K., Pereira D.M., Perez-Ruiz F., Perico N., Pervaiz A., Petzold M., Phillips M.R., Pigott D.M., Pinho C., Plass D., Pletcher M.A., Polinder S., Postma M.J., Pourmalek F., Purcell C., Qorbani M., Radfar A., Rafay A., Rahimi-Movaghar V., Rahman M., Ur Rahman M.H., Rai R.K., Ranabhat C.L., Rankin Z., Rao P.C., Rath G.K., Rawaf S., Ray S.E., Rehm J., Reiner R.C., Reitsma M.B., Remuzzi G., Rezaei S., Rezai M.S., Rokni M.B., Ronfani L., Roshandel G., Roth G.A., Rothenbacher D., Ruhago G.M., Rizwan S.A., Saadat S., Sachdev P.S., Sadat N., Safdarian M., Saf S., Safiri S., Sagar R., Sahathevan R., Salama J., Salamati P., Salomon J.A., Samy A.M., Sanabria J.R., Sanchez-Niño M.D., Santomauro D., Santos I.S., Milicevic M.M.S., Sartorius B., Satpathy M., Shahraz S., Schmidt M.I., Schneider I.J.C., Schulhofer-Wohl S., Schutte A.E., Schwebel D.C., Schwendicke F., Sepanlou S.G., Servan-Mori E.E., Shackelford K.A., Shaikh M.A., Shamsipour M., Shamsizadeh M., Islam S.M.S., Sharma J., Sharma R., She J., Sheikhbahaei S., Shey M., Shi P., Shields C., Shigematsu M., Shiri R., Shirude S., Shiue I., Shoman H., Shrime M.G., Sigfusdottir I.D., Silpakit N., Silva J.P., Singh A., Singh J.A., Skiadaresi E., Sligar A., Smith A., Smith D.L., Smith M., Sobaih B.H.A., Soneji S., Sorensen R.J.D., Soriano J.B., Sreeramareddy C.T., Srinivasan V., Stanaway J.D., Stathopoulou V., Steel N., Stein D.J., Steiner C., Steinke S., Stokes M.A., Strong M., Strub B., Subart M., Sufyan M.B., Sunguya B.F., Sur P.J., Swaminathan S., Sykes B.L., Tabarés-Seisdedos R., Tadakamadla S.K., Takahashi K., Takala J.S., Talongwa R.T., Tarawneh M.R., Tavakkoli M., Taveira N., Tegegne T.K., Tehrani-Banihashemi A., Temsah M.-H., Terkawi A.S., Thakur J.S., Thamsuwan O., Thankappan K.R., Thomas K.E., Thompson A.H., Thomson A.J., Thrift A.G., Tobe-Gai R., Topor-Madry R., Torre A., Tortajada M., Towbin J.A., Tran B.X., Troeger C., Truelsen T., Tsoi D., Tuzcu E.M., Tyrovolas S., Ukwaja K.N., Undurraga E.A., Updike R., Uthman O.A., Uzochukwu B.S.C., Van Boven J.F.M., Vasankari T., Venketasubramanian N., Violante F.S., Vlassov V.V., Vollset S.E., Vos T., Wakayo T., Wallin M.T., Wang Y.-P., Weiderpass E., Weintraub R.G., Weiss D.J., Werdecker A., Westerman R., Whetter B., Whiteford H.A., Wijeratne T., Wiysonge C.S., Woldeyes B.G., Wolfe C.D.A., Woodbrook R., Workicho A., Xavier D., Xiao Q., Xu G., Yaghoubi M., Yakob B., Yano Y., Yaseri M., Yimam H.H., Yonemoto N., Yoon S.-J., Yotebieng M., Younis M.Z., Zaidi Z., El Sayed Zaki M., Zegeye E.A., Zenebe Z.M., Zerfu T.A., Zhang A.L., Zhang X., Zipkin B., Zodpey S., Lopez A.D., Murray C.J.L., GBD 2016 Causes of Death Collaborators (2017)
      Background: Monitoring levels and trends in premature mortality is crucial to understanding how societies can address prominent sources of early death. The Global Burden of Disease 2016 Study (GBD 2016) provides a comprehensive ...

    • Helicobacter pylori infection and respiratory diseases: A review 

      Roussos, A.; Philippou, N.; Gourgoulianis, K. I. (2003)
      In the past few years, a variety of extradigestive disorders, including cardiovascular, skin, rheumatic and liver diseases, have been associated with Helicobacter pylori (H. pylori) infection. The activation of inflammatory ...

    • Hepatitis B virus and intrahepatic cholangiocarcinoma 

      Gatselis, N. K.; Tepetes, K.; Loukopoulos, A.; Vasiou, K.; Zafiriou, A.; Gioti, C.; Dalekos, G. N. (2007)
      Intrahepatic cholangiocarcinoma (ICC) is a rare type of primary liver cancer that arises from intrahepatic bile ducts. Its etiopathogenesis has been considered to be independent of the presence of chronic viral hepatitis ...

    • Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B 

      Papatheodoridis G.V., Sypsa V., Dalekos G.N., Yurdaydin C., Van Boemmel F., Buti M., Calleja J.L., Chi H., Goulis J., Manolakopoulos S., Loglio A., Voulgaris T., Gatselis N., Keskin O., Veelken R., Lopez-Gomez M., Hansen B.E., Savvidou S., Kourikou A., Vlachogiannakos J., Galanis K., Idilman R., Esteban R., Janssen H.L.A., Berg T., Lampertico P. (2020)
      Background & Aims: Hepatocellular carcinoma (HCC) may develop in patients with chronic hepatitis (CHB) even after 5 years of oral therapy and cannot be easily predicted. We assessed predictors of HCC development and the ...

    • Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort 

      Papatheodoridis, G. V.; Manolakopoulos, S.; Touloumi, G.; Nikolopoulou, G.; Raptopoulou-Gigi, M.; Gogos, C.; Vafiadis-Zouboulis, I.; Karamanolis, D.; Chouta, A.; Ilias, A.; Drakoulis, C.; Mimidis, K.; Ketikoglou, I.; Manesis, E.; Mela, M.; Hatzis, G.; Dalekos, G. N. (2015)
      Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in patients treated with the current first-line antivirals remains uncertain. ...